Navigation Links
OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
Date:2/8/2017

SAN DIEGO, Feb. 8, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical data on ImmunoPulse® IL-12, its lead program focused on oncology, at the upcoming 2017 American Association for Cancer Research & Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium. In addition, Punit Dhillon, President & CEO, will present a corporate overview at two investment conferences in February, including: the 19th Annual BIO CEO & Investor Conference and Source Capital Group's 2017 Disruptive Growth & Healthcare Conference.

2017 ASCO-SITC Clinical Immuno-Oncology Symposium Dr. Alain Algazi, Associate Clinical Instructor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, will present an oral and poster presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium to be held on February 23-24, 2017, in Orlando, FL.

Details of the presentation are as follows:

Abstract Title: Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12) (Abstract ID #78) Session Title: Activating the Immune System-New Clinical Approaches Date and Time: February 23, 2017 at 11:30 a.m. – 1:00 p.m. (poster) & 3:30 p.m. – 5:00 p.m. EST (oral) Location: Hyatt Regency Orlando

Further details on this ASCO-SITC oral and poster presentation will be provided in upcoming Company communications. For more information about this symposium, please visit: http://immunosym.org/

The 19th Annual BIO CEO & Investor Conference Mr. Dhillon will present a corporate overview at The 19th Annual BIO CEO & Investor Conference on February 14 at 3:00 p.m. EST at The Waldorf Astoria in New York City.

To view to the live webcast, please access the following link at the time of the presentation: http://www.veracast.com/webcasts/bio/ceoinvestor2017/98226117037.cfm. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.

For more information about this conference, please visit: https://www.bio.org/events/bio-ceo-investor-conference

Source Capital Group's 2017 Disruptive Growth & Healthcare Conference Mr. Dhillon will present a corporate overview at Source Capital Group's 2017 Disruptive Growth & Healthcare Conference on February 15 at 3:00 p.m. EST at Convene in New York City.

For more information about this conference, please visit: www.DisruptNYC.com.

About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT: Punit Dhillon President & Chief Executive Officer OncoSec Medical Incorporated 855-662-6732 media@oncosec.com

Media: Laura Radocaj Dian Griesel Int'l. 212-825-3210

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-new-clinical-data-from-phase-2-combination-study-at-asco-sitc-clinical-immuno-oncology-symposium-and-corporate-updates-at-two-investment-conferences-in-february-300403831.html


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. OncoSec Announces First Quarter Financial Results for Fiscal Year 2017
2. OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016
3. OncoSec Appoints Sharron Gargosky, PhD, as Head of Clinical Development and Operations
4. OncoSec Opens New Headquarters and Research Facility in San Diego
5. OncoSec Announces First Quarter Results for Fiscal Year End 2016
6. OncoSec to Host First Quarter Financial Results Conference Call on December 8, 2015
7. OncoSec Medical Closes $7.5 Million Registered Direct Offering
8. OncoSec Announces $7.5 Million Registered Direct Offering
9. OncoSec Enrolls First Patient in Biomarker-Focused Pilot Study in Triple Negative Breast Cancer
10. OncoSec Issues Annual Letter To Shareholders
11. OncoSec Announces Fourth Quarter and YTD Results for Fiscal Year End 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ROCKVILLE, Md. , March 27, 2017 /PRNewswire/ ... $108.5 billion for 2016, according to a new ... patients, medical lab testing is performed to evaluate ... determine individual therapy, among other reasons.  The healthcare ... Services Market , provides an overview of ...
(Date:3/27/2017)... The new research portal will give ... reports on Valero Energy , offering extensive market research ... ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest trend gaining ... Ethanol today, even though touted as a green alternative to ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the world’s ... to new and improved ways of treating coronary artery disease (CAD). Lam is ...
(Date:3/27/2017)... Israel , March 27, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... party insurance coverage option for U.S. consumers who want ... DarioHealth has signed strategic alliance agreements with ... verify insurance coverage benefits, and if approved, will supply ...
Breaking Biology Technology:
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/13/2017)... of security: Biometric Face Matching software  Continue Reading ... ... match face pictures against each other or against large databases. The recognition of ... ... for biometric Face Matching on the market. The speed is at 100 million ...
Breaking Biology News(10 mins):